ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Consumer Discretionary / NUTX
LQDT (73) RDWR (58) RSKD (54) AHG (32) ⌘ Pro Terminal →

Nutex Health Inc. (NUTX) — RQD Stock Rating Cockpit

$185.60 -7.27% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $183.62

Nutex Health Inc. (NUTX) earns a Roarable Rating of A- (Buy) with 84/100 RQD Confidence. High-quality cash engine (50.8% gross margin, 85% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE A- • STRONG BUY Cap $1.37B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NUTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NUTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Nutex Health Inc. (NASDAQ: NUTX) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 84/100 at a spot price of $185.60 (-7.27% 1D, market cap $1.37B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 18/20, and Executive Insider Alignment 19/20. Across 1009 tracked Consumer Discretionary issuers, NUTX ranks #6 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NUTX compare to LQDT and RDWR in the Consumer Discretionary sector?
▼

Within the Consumer Discretionary sector (Business Services), NUTX carries a Roarable A- (84/100 RQD), trailing P/E of 20.3x, gross margin of 50.8%, and ROIC of 85.0%. By comparison, LQDT (Liquidity Services Inc.) holds a B grade (73/100 RQD, P/E 50.5x, ROIC 12.9%, cap $1.40B) and RDWR (Radware Ltd.) posts a D+ grade (58/100 RQD, P/E 76.5x, ROIC 3.7%, cap $1.46B). Among the 5-stock peer group, NUTX leads on earnings multiple (20.3x) while NUTX leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NUTX?
▼

Per NUTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001479681), Nutex Health Inc. generated $875.3M in revenue (+82.4% YoY), $70.8M in net income, and $245.6M in free cash flow against $918.5M in total assets and $29.2M in total debt. Key quantitative strengths: Strong cash generator (50.8% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $183.61 (-1.07%)🧬 Cannibal Buyback (-3.20% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 28.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 84/100 (A-) historically ranked in the Top 6% of excess returns over the next 90 days (+8.9% avg 90D alpha vs SPY • 72.6% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSTRONG BUY • A-
025507510084
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A- · Rk A-
Cash (19)Whales (12)SEC (16)Macro (18)CEO (19)
Each axis scored 0–20
12M PRICE TARGET CONE+11.7% Base Target
$245 Bull$207 Base$152 Bear
📬 FREE NUTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NUTX)Realized 20D OHLCV Swing Band: ±11.3%
Deterministic 5-Pillar Attribution (84/100 Composite)
🔍 WHY NUTX SCORES 84/100 (A-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 28.1% FCF Margin ($245.6M FCF) & 50.8% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+19/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy • Cannibal Buyback (-3.20% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning12/20 pts (-8 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
92
Grade A+$204.36-2.6% Next Q
Q2 (-2Q)
89
Grade A$198.99+4.7% Next Q
Q3 (-1Q)
87
Grade A$208.25-10.9% Next Q
Current
84
Grade A-$185.60+8.9% Hist 90D α
Trajectory: A+ (92) → A- (84)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the NUTX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 84/100 (A-) score, NUTX faces multiple-compression risk if 20.3x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-3.20% YoY Shares) — any gross margin slip below 48.3% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($203.98) or 200D SMA ($150.91) invalidates the momentum regime and cuts Target Base ($207.32) toward Bear Floor ($152.19).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NUTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NUTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 84%NO 16%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
4730 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.75>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
9 / 99-Pt Accounting
52-WEEK LASER RANGE71% OF RANGE
L: $84$185.60H: $226
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (50.8% gross margin and healthy balance-sheet cushion).

Factor Grade: A+RQD 19 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: B+RQD 31 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: A-RQD 34 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on NUTX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (95)

85.0% ROIC with 50.8% gross margin and 17.07% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 3.75 and Piotroski 9/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (82)

31/40 institutional & smart-money positioning score with 18/20 macro alignment.

Bull Case: Why Buyers Like NUTX
  • ✓Strong cash generator (50.8% gross margin)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (NUTX Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NUTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +26.11%🛡️ HOLDING TREND SUPPORT
2026-11-03O $210.1H $210.1L $185.6C $185.6VOL 120.1K
RES: $256.0SUP: $176.4SMA50: $204.0SMA200: $150.9
$234.7$199.3$163.8$128.4$92.90RES $256.0SUP $176.4$185.62026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NUTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NUTX Butterfly Map → + Track NUTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
13.9%/yr Implied 5Y Growth

vs. +82.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NUTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NUTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NUTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NUTX)

Consumer Discretionary Rank #6 of 1009 ⚔️ LQDT vs NUTX Full Matrix →

1. Head-to-Head Consumer Discretionary Peer Comparison (NUTX vs. LQDT, RDWR, RSKD, AHG)

Industry: Business Services (88 Tracked Issuers)

Across 1009 tracked Consumer Discretionary securities in the Roarable RQD universe, Nutex Health Inc. (NUTX) ranks #6 by composite RQD confidence (84/100, grade A-) and #467 by equity capitalization ($1.37B). Within this direct 5-issuer industry benchmark cohort, NUTX leads on earnings valuation at 20.3x trailing P/E, while NUTX leads on capital efficiency and profitability with 85.0% ROIC and 50.8% gross margin. NUTX currently leads its immediate peer cohort in composite quantitative strength at 84/100 (A-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NUTX ACTIVE
Nutex Health Inc.
A- 84/100 20.3x 50.8% 85.0% -7.27% $1.37B Benchmark Subject
LQDT
Liquidity Services Inc.
B 73/100 50.5x 43.8% 12.9% +0.05% $1.40B /lqdt-vs-nutx →
RDWR
Radware Ltd.
D+ 58/100 76.5x 80.7% 3.7% -5.61% $1.46B /rdwr-vs-nutx →
RSKD
Riskified Ltd. (Class A)
D+ 54/100 — 51.7% -20.3% -1.05% $1.17B /rskd-vs-nutx →
AHG
Akso Health Group ADS
E 32/100 — -0.1% — +4.17% $1.08B /ahg-vs-nutx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001479681 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nutex Health Inc. (NUTX) reported GAAP revenue of $875.3M (+82.4% vs. FY2024 revenue of $479.9M , and +253.4% cumulative change since FY2023) , GAAP net income of $70.8M, operating cash flow of $248.1M, and free cash flow of $245.6M (+1078.0% YoY). On the balance sheet, NUTX closed FY2025 with $918.5M in total assets against $29.2M in total debt (Altman Z-Score: 3.75, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $875.3M $70.8M $248.1M $245.6M $918.5M $29.2M
FY2024 (FY) 2024-12-31 $479.9M $52.1M $23.2M $20.8M $655.3M $22.5M
FY2023 (FY) 2023-12-31 $247.6M -$45.8M $1.3M $1.3M — —

3. NUTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NUTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Nutex Health Inc. (NASDAQ: NUTX) is rated A- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 84/100 at a spot price of $185.60 (-7.27% 1D, market cap $1.37B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 12/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 18/20, and Executive Insider Alignment 19/20. Across 1009 tracked Consumer Discretionary issuers, NUTX ranks #6 in composite RQD confidence.

How does NUTX compare to LQDT and RDWR in the Consumer Discretionary sector?

Within the Consumer Discretionary sector (Business Services), NUTX carries a Roarable A- (84/100 RQD), trailing P/E of 20.3x, gross margin of 50.8%, and ROIC of 85.0%. By comparison, LQDT (Liquidity Services Inc.) holds a B grade (73/100 RQD, P/E 50.5x, ROIC 12.9%, cap $1.40B) and RDWR (Radware Ltd.) posts a D+ grade (58/100 RQD, P/E 76.5x, ROIC 3.7%, cap $1.46B). Among the 5-stock peer group, NUTX leads on earnings multiple (20.3x) while NUTX leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NUTX?

Per NUTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001479681), Nutex Health Inc. generated $875.3M in revenue (+82.4% YoY), $70.8M in net income, and $245.6M in free cash flow against $918.5M in total assets and $29.2M in total debt. Key quantitative strengths: Strong cash generator (50.8% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NUTX trading relative to its 50-day, 200-day, and 52-week technical levels?

NUTX last traded at $185.60 (-7.27% on volume of 258,119 shares), positioning the stock -9.01% below its 50-day simple moving average ($203.98) and +22.99% above its 200-day simple moving average ($150.91). Across its 52-week range of $83.99 to $226.16, NUTX sits at the 71.5% percentile with a 14-day RSI of 47.0 (NEUTRAL RANGE) and an implied next-earnings move of ±11.3% ($164.63 to $206.57).

Direct Sub-Reports: NUTX RQD Cockpit NUTX 12M Forecast NUTX Earnings & Move NUTX Dividends & DRIP NUTX Insiders & 13F NUTX Whale Options NUTX Profit Sankey NUTX News & Why
ROARABLE RATING BRIEF • RQD 84/100 (A-) ✓ SEC XBRL & RQD VERIFIED

NUTX — Nutex Health Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Nutex Health Inc. (NUTX) earns a live Roarable RQD composite score of 84/100, corresponding to a A- letter grade (Roarable Buy) at a spot price of $185.60 (-7.27% 1D, market capitalization $1.37B).

  • Fundamental Cash Engine (19/20): Anchored by return on invested capital (ROIC) of 85.0%, gross margin of 50.8%, operating margin of 31.5%, and free cash flow yield of 17.07%.
  • Whale 13F & Options Flow (12/20) + Insider Conviction (19/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (18/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 3.75, Piotroski F-Score of 9/9, and Debt/Equity of 0.09x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Nutex Health Inc. (NUTX) is a NASDAQ-listed company classified in the Consumer Discretionary sector and Business Services industry,. — for detailed product lines, customer base, or revenue-generation model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Nutex Health Inc. (NUTX) reported $875.3M in annual revenue (up from $479.9M in FY2024, +82.4% YoY) and $70.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($247.6M revenue, -$45.8M net income) through FY2025, NUTX scaled operating cash flow to $248.1M and free cash flow to $245.6M, backed by $918.5M in total assets against $29.2M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (A- • RQD 84/100): Strong cash generator (50.8% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 19/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $83.99 – $226.16 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 20.3x trailing P/E and 4.6x EV/EBITDA against 31.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — Investors should not infer supplier or customer ripples from the sector label alone.

  • Key Question #1: Can NUTX sustain or expand its 31.5% operating margin and 85.0% ROIC against Business Services peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $875.3M and free cash flow of $245.6M, how will capital allocation balance growth reinvestment against $29.2M in total debt?
  • Key Question #3: How sensitive is NUTX's 17.1x forward P/E multiple to Consumer Discretionary capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NUTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Nutex Health Inc. (NUTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NUTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NUTX Bull vs. Bear Conversation Board — What's Your Call at $185.60?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NUTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NUTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $240.18 (+20.0%)
📌 Pinned Debate

Per the RQD rating, cash generation is exceptional, with ROIC of 85% and an FCF yield of 17.07% at a P/E (TTM) of 20.3.

Long NUTX at $200.15 targeting $240.18. Per the RQD rating, cash generation is exceptional, with ROIC of 85% and an FCF yield of 17.07% at a P/E (TTM) of 20.3.. Institutional whale score is 12/20 and the risk/reward vs. the $83.99 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@TapeReader_Pro Agree on the RQD 84/100 quality, though with 1.0 beta I'm scaling in with half-size at $200.15 and keeping dry powder in case we test $186.14.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $166.12 (-17.0%)
Spot @ $200.15

Net margin of 8.1% sits far below the 31.5% operating margin, and FY 2024 FCF of $20.8M contrasts sharply with FY 2025 FCF of $245.6M.

I respect the product at Nutex Health Inc., but the stock at $200.15 is a different story. Net margin of 8.1% sits far below the 31.5% operating margin, and FY 2024 FCF of $20.8M contrasts sharply with FY 2025 FCF of $245.6M.. FCF yield is 17.07% and RQD sits at 84/100 (A-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%